A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, ...

Aycock was diagnosed with COVID-19 and got a prescription for Paxlovid, but it was going to cost him $1,400. Aycock said he tried his best to get his hands on the prescription. I ...

At Shionogi, a Japanese pharmaceutical company, executives pointed out that COVID is still flaring in Japan. In Japan, ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | ...

MEDICAL CARE CAN BE EXPENSIVE, AS WE ALL KNOW, BUT THAT’S WHERE HEALTH INSURANCE IS SUPPOSED TO COME IN TO ALLEVIATE THE COST ...

COVID-19 clinical rebound following treatment with nirmatrelvir-ritonavir (Paxlovid) was generally mild and associated with favorable outcomes.

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ...

NEW YORK — A boost from Covid-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher ...

It is a critical quarterly report for Pfizer, which is grappling with a proxy battle waged by the activist investor Starboard ...

Pfizer's third-quarter performance exceeded expectations, driven by a surge in demand for its COVID-19 treatment Paxlovid, ...

Pfizer reported higher-than-expected profit due to strong sales of COVID-19 treatment Paxlovid. Despite this success, the ...